- Recruiting
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Updated: Jun 15, 2022
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Recruitment Status: Enrolling by invitation

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Sponsor
Collaborator
California Institute for Regenerative Medicine (CIRM)
Multiple Locations
ClinicalTrials.gov Identifier: NCT03741127
Official Title: Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
First Posted: November 14, 2018
Click here for details on Clinicaltrials.gov
CART - BCMA : National Cancer Institute
Biological: P-BCMA-101 CAR-T cells